Oslo, 30 June 2021 - Reference is made to the announcement by EXACT Therapeutics
AS ('EXACT-Tx' or the 'Company') on 7 June 2021 regarding the issuance of 24,417
new shares in the Company, for the purpose of issuing shares under the Company's
restricted stock unit (RSU) program to its Board members.
The share capital increase pertaining to the issuance of the new shares has now
been registered with the Norwegian Register of Business Enterprises. The
Company's new registered share capital is NOK 119,968.668 divided into
29,992,167 shares, each with a nominal value of NOK 0.004.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com